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•	 Selection of a suitable host is an important step in recombinant protein production. 
•	 Escherichia coli cells are the most attractive host in therapeutic protein production.
•	 Engineered strains had developed to produce active protein with suitable conformation in industrial scale.
•	 Classical mutagenesis & genome engineering are two important strain engineering strategies.
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ABSTRACT
Selection of a suitable host strain is an important step in recombinant production of 
heterologous proteins. As the prokaryotic systems and especially Escherichia coli (E. coli) 
cells are the most attractive host in therapeutic protein production, various derivatives 
of this organism have been developed to overcome the limitations exist in recombinant 
protein	 production,	 such	 as	 inefficient	 expression	 and	 folding	 of	 target	 proteins	 with	
eukaryotic origin. This review summarized key strategies for E. coli engineering and 
introduced some new and applicable engineered E. coli strains that produce more complex 
proteins for therapeutic and research use in the future.
Engineered Recombinant Protein Production Systems Originated from 
Escherichia coli
Review Article
Trends in Peptide and Protein Sciences
Volume 3 (2018): e2
Article history:
Received: 17 February 2018
Accepted: 7 March 2018 
Introduction 
Recombinant proteins have vast applications in research, 
diagnosis	and	therapeutic	fields	(Andersen	and	Krummen,	
2002;	 Biswal	 et	 al.,	 2016).	 In	 general,	 specific	 protein	
isolation from natural sources as had done in the past, is 
an	inefficient	and	laborious	work	as	well	as	having	safety	
and availability challenges. Introduction of recombinant 
technology get rid of these limitations through cloning 
the protein coding DNA in an appropriate vector and 
foreign expression in a suitable host. Nowadays, different 
expression systems use for recombinant protein production 
, including mammalian cells like CHO, bacterial cells like 
Escherichia coli, yeast, cell-free system, transgenic plants 
and animals (Ranjbari et al., 2015). Escherichia coli is 
preferable choice for production of recombinant proteins 
both on a lab scale and in industry, as at this time, around 
one third of the approved therapeutic proteins are being 
produced in this prokaryotic host (Baeshen et al., 2015). 
Owing to its low cost, the ease of genetic manipulation, 
rapid growth, high yield of the product, cost effectiveness, 
and easy scale-up process, E. coli	is	considered	as	the	first	
choice for industrial large-scale production of therapeutic 
proteins, particularly non-glycosylated ones (Jia and Jeon, 
2016). Other attractive features for industrial applications 
are the availability of various E. coli expression vectors 
and strains, relatively easy protein folding mechanisms, 
and bioprocess technologies. The limitation in post 
translational	modifications	like	glycosylation,	acetylation,	
phosphorylation, and proteolytic processing, restrict 
its application in the production of slightly complex 
eukaryotic proteins (Jia and Jeon, 2016). Several 
technological strategies have emerged new features in 
the E. coli expression system and resulted in several high 
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environment, newly synthesized proteins are at great risk 
of misfolding and aggregation. To avoid these risks, cells 
provide a collection of molecular chaperones. A major 
role of these chaperones is to protect newly synthesized 
polypeptide chains and also, assembled subunits from 
aggregating into nonfunctional structures. Recombinant 
protein expression in E. coli often results in the formation 
of inclusion bodies which are the insoluble aggregates 
form of proteins. Co-expression of chaperone can be a 
good approach from several techniques applied for the 
prevention of inclusion bodies formation. Chaperones 
assist newly synthesized proteins fold into their native 
conformation and shield exposed hydrophobic patches 
involved in the initiation of protein aggregation (Hartl et 
al.,	2011;	Kim	et	al.,	2013).	
Expression	of	disulfide-bonded	proteins	using	E.	coli	
The other challenge with the production of recombinant 
proteins in E. coli	is	formation	of	favored	disulfide	bonds.	
The cytoplasm of E. coli is usually retained in reduced 
state and the activity of thioredoxin and glutaredoxin/
glutathione enzyme systems result in the prevention of 
disulfide	 bonds	 formation.	Also,	 the	 protein	 of	 interest	
is expressed in the cytoplasm in the form of inclusion 
bodies, in most cases, and needs to be solubilized and re-
folded in vitro. Some strains with mutations in thioredoxin 
reductase (trxB) and glutathione reductase (gor) genes 
have oxidizing condition in cytoplasm and therefore, can 
enhance	disulfide	bond	formation	in	the	E. coli cytoplasm. 
It should be considered that these strains can not reduce 
ribonucleotides and therefore, need exogenous reductant, 
such as dithiothreitol (DTT) for growth (Stewart et al., 
1998;	De	Marco,	2009;	Gąciarz	et	al.,	2017).	
Engineered E.coli strains
The ultimate goal of microorganism engineering is to 
design strains that can produce active protein with suitable 
conformation in industrial scale. Strain engineering is a 
very promising approach in this regard that can evolve 
engineered E. coli	 strains	 with	 significantly	 improved	
features	 for	 efficient	 production	 of	 recombinant	 protein	
(Makino et al., 2011). Nowadays, scientists use different 
methods to produce strains with increased production 
capacity, decreased toxicity caused by overproduction, 
optimization of cellular pathways and physiology (Santos 
and Stephanopoulos, 2008). Classical mutagenesis and 
genome engineering methods are two important groups of 
strain engineering strategies. Some classical mutagenesis 
strategies in bacteria through the enhancement of 
recombinant protein production consist of spontaneous 
chromosomal mutagenesis (Miroux and Walker, 1996), 
chromosomal mutagenesis using chemical mutagens or 
mutator genes (Massey-Gendel et al., 2009), transposon 
performance strains. These novel engineered strains, as the 
genetically	modified	E. coli can express complex proteins, 
including growth factors or full-length glycosylated 
antibodies	 (Löffler	 et	 al.,	 2016).	 Recent	 studies	 have	
demonstrated that these promising genetically engineered 
strains of E. coli enhanced markedly the production 
capacities for recombinant proteins. 
Important considerations for recombinant 
protein production using E. coli 
There are different strategies in E. coli engineering that 
result in improved protein synthesis and/or folding. 
Rather than strain selection, some other concerns have 
to	be	considered	 in	an	efficient	protein	production	 in	E. 
coli using recombinant DNA technology. Some of these 
concerns are:
Codon Usage in E. coli
Genes that contain rare codons of E. coli may be 
inefficiently	 expressed	 by	 this	 organism,	 as	 the	 amount	
of each transfer RNAs (tRNAs) is dependent on the 
frequency of that codon in natural genomic content of 
organism. Therefore, codon optimization is an essential 
step of process design to increase the expression level 
of heterologous recombinant proteins. In this approach 
synonymous codon mutations are performed in 
messenger RNA (mRNA) coding regions. Most amino 
acids can be encoded by more than one synonymous 
codon. Appropriate codon usage in the design of coding 
gene	can	have	a	distinct	influence	on	protein	expression	
efficiency	(Sharp	et	al.,	1988;	Burgess-Brown	et	al.,	2008;	
Mauro, 2018). Ghavim et al. demonstrated that codon 
optimization at N-terminal of the recombinant human 
growth	 hormone	 gene	 could	 significantly	 increase	 the	
expression of human growth hormone in E. coli (Ghavim 
et al., 2017). 
Enhanced	mRNA	stability
The half-life of mRNA can effect on translation and 
protein synthesis. So, in E.coli such other bacteria, mRNA 
stability is rate limiting step in translation and, hence, in 
recombinant protein production (Makino et al., 2011). 
RNase E is an essential E. coli endonuclease, which has 
an important role on mRNA degradation at C-terminal 
region. Mutation in this region decrease the activity of 
RNase E, and therefore, increase mRNA stability and 
consequent protein expression (Lopez et al., 1999).
Chaperone	co-expression	strategy
The biological activity of proteins is dependent on 
their three-dimensional fold. However, in the cellular 
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mutagenesis (Makino et al., 2011), and co-expression of 
the	ASKA	library	(a	complete	set	of	E. coli	K	-12	ORF	
Archive) (Skretas and Georgiou, 2009). Also, there 
are some genome engineering strategies like, global 
transcription machinery engineering (gTME) (Alper 
and	 Stephanopoulos,	 2007;	 Lee	 et	 al.,	 2008;	 Klein-
Marcuschamer	 et	 al.,	 2009),	 Libraries	 of	 artificial	 zinc	
fingers	 (Park	 et	 al.,	 2003;	 Park	 et	 al.,	 2005;	 Lee	 et	 al.,	
2008), trackable multiplex recombineering (TRMR) 
(Warner	et	al.,	2010)	and	genome	shuffling	(Patnaik	et	al.,	
2002; Zhang et al., 2002; Dai and Copley, 2004) which 
can enhance recombinant protein production in E. coli. 
Lemo21 (DE3) 
E. coli BL21 (DE3) is a common used strain to
overexpress recombinant proteins. In this approach, the
target protein gene is located under control of the T7
promoter of plasmid, and is recognized by the T7 RNA
polymerase	 (RNAP).	The	expression	of	T7	RNAP	gene
on the chromosome is controlled by the non-titratable,
IPTG-inducible	 lacUV5	 promoter.	 In	 this	 system,
proteins expression leads to inclusion bodies formation
and their accumulation and in some case, uncontrolled
protein expression can lead to the growth inhibition.
So, as a general evidence, less expression of proteins
generate more production of protein in the desired form,
particularly for membrane protein expression (Wagner
et al., 2008). Fine tuning of T7 expression can control
the challenge of inclusion body formation and the toxic
effect of recombinant proteins on growth. Lemo21 
(DE3) is the next generation of E. coli that has more 
features than BL21(DE3), can serve tunable expression 
of challenging clones. Tunable expression is achieved by 
changing lysozyme (lysY) level, as the natural inhibitor 
of T7 RNA polymerase, by adding L-rhamnose to the 
expression culture in the range of 0 to 2000 µM (Fig. 1) 
(Schlegel et al., 2012). Schlegel et al. studied the effect of 
different concentrations of rhamnose on the expression of 
membrane proteins in Lemo21 (DE3) and observed that 
this strain could cause overexpression of these proteins 
and may be very suitable for optimizing the production of 
membrane proteins (Schlegel et al., 2012). Lemo21(DE3) 
can highly expressed  membrane proteins at different 
concentrations of rhamnose. Lemo21 (DE3) is run similar 
to a pLysS containing strain when grow in the absence of 
rhamnose. However, optional addition of rhamnose is led 
to	the	favored	expression	of	the	specific	protein.	Tuning	
the expression level of less soluble proteins, may also 
result in more soluble, properly folded protein (Wegerer 
et al., 2008; Marschall et al., 2017).
NiCo21 (DE3) strain
This strain is derived from BL21 (DE3) strain applied 
in	 some	 specific	 recombinant	 production	 containing	
metal	 binding	 domain.	 Immobilized	 metal	 affinity	
chromatography (IMAC) is a method of choice for isolation 
of recombinant protein produced as a fusion protein 
containing a metal binding domain in E. coli strains. For 
Figure1. Lemo21	(DE3)	strain;	different	concentrations	of	L-rhamnose	control	T7RNAP	and	recombinant	protein	expression	(Womack,	2011).
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example, polyhistidine tag (6–10 consecutive His amino 
acids)	offers	high	affinity	to	immobilized	metals	such	as	
nickel	and	cobalt	and	routinely	leads	to	a	highly	purified	
protein with greater than 80% purity, through a single 
metal	affinity	column.	E. coli and other expression hosts 
have numerous essential proteins with metal cofactors. 
These endogenous metal-binding proteins interfere with 
the recombinant protein in the binding to IMAC resins 
and complicate isolation of the desired target protein and 
as	a	result,	final	product	is	contaminated	with	significant	
amounts of endogenous E. coli metal binding proteins 
(Robichon et al., 2011). 
The NiCo21 (DE3) is an engineered protein expression 
strain with minimized E. coli protein contamination. In this 
strain, Glutamine--fructose-6-phosphate aminotransferase 
(GlmS) gene is mutated and three other proteins (SlyD, 
ArnA and Can) are tagged by chitin-binding domain 
(CBD) originating from Bacillus circulans, that eliminate 
cross contamination of IMAC resin with endogenous 
protein	 and	 enable	 rapid	 purification	 of	 SlyD,	 ArnA	
and	Can	protein	by	chitin	affinity	chromatography	(Fig.	
2) (Bolanos-Garcia and Davies, 2006; Robichon et al., 
2011). 
Robichon et al. designed and characterized two E. coli 
BL21(DE3) derivatives, NiCo21(DE3) and NiCo22(DE3), 
which express the E. coli endogenous proteins SlyD, Can, 
ArnA, and AceE (optionally) as fusion proteins with a 
chitin binding domain (CBD) and the protein GlmS, with 
six surface histidines replaced by alanines. E. coli CBD-
tagged proteins were eliminated from the IMAC elution 
fraction	using	a	chitin	column,	while	the	modification	of	
GlmS	results	in	loss	of	affinity	for	nickel-containing	resin.	
These engineered strains are thus preferred expression 
strains for obtaining recombinant His-tagged target 
proteins with no host protein contamination and increased 
purification	level	(Robichon	et	al.,	2011).
NEB Express Competent E. coli 
NEB Company introduced a chemically competent E. 
coli	strain	suitable	for	high	efficiency	transformation	and	
protein	 expression.	 Transformation	 efficiency	 of	 NEB	
strain is 0.6-1 x 109	cfu/μg	of	pUC19	DNA.	This	strain	
is	 deficient	 in	 proteases	 of	 Lon	 and	OmpT	 and	 can	 be	
suitable for non-T7 protein expression. Different NEB 
stains offer variable levels of expression control, resistant 
to phage T1 and also, show extremely high transformation 
efficiencies	 (Samuelson,	 2011).	 E. coli ER2523 (NEB 
Express) is an enhanced BL21 derivative available with 
or without the added control from lacIq. This engineered 
strain is recommended host strain for pMALTM	 Protein	
Fusion	 and	 Purification	 System.	 The	 pMALTM	 Protein	
Fusion	 and	 Purification	 System	 clone	 the	 desired	 gene	
in a pMALTM vector, down-stream from the malE 
gene,	 which	 encodes	 maltose-binding	 protein	 (MBP).	
Therefore,	 an	 MBP-target	 fusion	 protein	 is	 expressed	
and	then,	purified	by	one-step	affinity	purification,	which	
show	 specific	 binding	 to	MBP.	This	 technique	 uses	 the	
strong Ptac promoter and the translation initiation signals 
of	MBP	results	in	large	amount	expression	of	the	fusion	
protein	 (Pryor	 and	 Leiting,	 1997;	 Kapust	 and	 Waugh,	
1999). 
Rossetta strain
One of BL21 derivatives that have designed to enhance 
the expression of eukaryotic proteins is Rossetta strain 
containing codons rarely used in E. coli. Rare tRNAs 
for	AGG,	AGA,	AUA,	CUA,	CCC	and	GGA	codons	by	
their native promoters are supplied with a compatible 
chloramphenicol-resistant plasmid. Thus, the Rosetta 
strains overcome the challenge of codon optimization 
for	 ″universal″	 protein	 translation	 in	E. coli. In Rosetta 
(DE3) pLysS, the rare tRNA genes are supplied with the 
same plasmids composed the T7 lysozyme gene.  The 
strain	of	DE3	(a	lysogen	of	λDE3)	carries	a	chromosomal	
copy of the T7 RNA polymerase gene under control of 
the	 lacUV5	promoter	 and	 therefore,	 can	 be	 suitable	 for	
protein production using pET vectors and induction with 
IPTG	(Tegel	et	al.,	2010;	Gopal	and	Kumar,	2013).
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Origami strain
Origami host strains as E. coli	 K-12	 derivatives	 have	
mutations in the thioredoxin reductase (trxB) and 
glutathione reductase (gor) genes. This engineered strain 
exhibited	 enhanced	 disulfide	 bond	 formation	 in	 the	E. 
coli cytoplasm. The Origami strains are kanamycin 
sensitive. These strains are recommended only for the 
production	 of	 proteins	 with	 essential	 disulfide	 bonds	
as a perquisite feature of proper folding, which avoid 
from	 undesired	 disulfide	 bond	 formation	 between	
polypeptides. There are different type of Origami 
strain	 base	 on	 different	 mutation	 and	 specific	 genes,	
like DE3, B(DE3), pLysS. The Origami B strains have 
combination of the desirable characteristics of BL21 
and Origami strains. B host strains have mutations 
in trxB and gor as the original Origami strains. They 
also have a lacZY mutation compared to BL21 that 
enable precise control of expression levels by adjusting 
the	 concentration	 of	 IPTG.	 DE3	strains	 are	 a	 lysogen	
of	λDE3	and	have	a	chromosomal	copy	of	the	T7	RNA	
polymerase	gene	under	control	of	the	lacUV5	promoter.	
pLysS strains express T7 lysozyme, which suppresses 
basal expression of T7 RNA polymerase prior to induction 





copies of genes that encode the rare tRNAs, which 
limit translation of heterologous proteins in E.coli. The 
BL21-CodonPlus	 (DE3)	 strains	 utilize	 the	 T7	 RNA	
polymerase promoter to enhance expression level. There 
are different codon plus strains, depend on the type of 
tRNAs	 encoded.	 BL21-CodonPlus-RIL	 contains	 extra	
copies	 of	 the	 argU,	 ileY,	 and	 leuW	 tRNA	 genes	 and	
encode tRNAs that recognize the arginine codons AGA 
and	AGG,	 the	 isoleucine	 codon	AUA,	 and	 the	 leucine	
codon	CUA.	These	codons	are	useful	for	the	expression	
of proteins originated from organisms with AT-rich 
genomes.	 BL21-CodonPlus-RP	 and	 BL21-CodonPlus	
(DE3)-RP	 cells	 contain	 extra	 copies	 of	 the	 argU	 and	
proL genes, encode tRNAs that recognize the Arg 
codons	AGA	and	AGG	and	the	Pro	codon	CCC,	suitable	
for the production of proteins from organisms that have 
GC-rich	 genomes.	 Both	 strains	 of	 BL21-CodonPlus-
RIL	and	BL21-CodonPlus-RP	can	be	used	with	vectors	
containing	non-T7	promoters.	BL21-CodonPlus	(DE3)-
RIPL	 cells	 contain	 extra	 copies	 of	 the	 argU,	 ileY,	 and	
leuW as well as the proL tRNA genes, that can be utilize 
for heterologous proteins from organisms with AT- or 
GC-rich	genomes	(Kleber-Janke	and	Becker,	2000;	Wu	
et al., 2004; Yin et al., 2007).
Conclusion 
According to the different novel improved prokaryotic 
expression systems that are currently used in recombinant 
production of proteins, selection of an appropriate strain 
regard to the aim of study and protein identity, has an 
important	effect	on	expression	efficacy	in	yield	and	final	
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